|
Gene: ASB2 |
Gene summary for ASB2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ASB2 | Gene ID | 51676 |
Gene name | ankyrin repeat and SOCS box containing 2 | |
Gene Alias | ASB-2 | |
Cytomap | 14q32.12 | |
Gene Type | protein-coding | GO ID | GO:0001947 | UniProtAcc | A0A024R6E7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51676 | ASB2 | LZE4T | Human | Esophagus | ESCC | 1.03e-11 | 3.53e-01 | 0.0811 |
51676 | ASB2 | LZE8T | Human | Esophagus | ESCC | 3.79e-04 | 1.91e-01 | 0.067 |
51676 | ASB2 | LZE6T | Human | Esophagus | ESCC | 1.64e-02 | 1.78e-01 | 0.0845 |
51676 | ASB2 | P2T-E | Human | Esophagus | ESCC | 7.88e-05 | 1.69e-01 | 0.1177 |
51676 | ASB2 | P4T-E | Human | Esophagus | ESCC | 7.46e-04 | 1.47e-01 | 0.1323 |
51676 | ASB2 | P5T-E | Human | Esophagus | ESCC | 6.77e-15 | 3.35e-01 | 0.1327 |
51676 | ASB2 | P8T-E | Human | Esophagus | ESCC | 1.07e-03 | 1.25e-01 | 0.0889 |
51676 | ASB2 | P11T-E | Human | Esophagus | ESCC | 9.23e-08 | 5.05e-01 | 0.1426 |
51676 | ASB2 | P15T-E | Human | Esophagus | ESCC | 9.98e-07 | 2.95e-01 | 0.1149 |
51676 | ASB2 | P23T-E | Human | Esophagus | ESCC | 1.27e-02 | 2.11e-01 | 0.108 |
51676 | ASB2 | P24T-E | Human | Esophagus | ESCC | 7.02e-26 | 6.79e-01 | 0.1287 |
51676 | ASB2 | P26T-E | Human | Esophagus | ESCC | 1.49e-11 | 3.47e-01 | 0.1276 |
51676 | ASB2 | P27T-E | Human | Esophagus | ESCC | 1.14e-02 | 1.88e-01 | 0.1055 |
51676 | ASB2 | P28T-E | Human | Esophagus | ESCC | 6.72e-03 | 1.69e-01 | 0.1149 |
51676 | ASB2 | P32T-E | Human | Esophagus | ESCC | 1.49e-08 | 3.04e-01 | 0.1666 |
51676 | ASB2 | P37T-E | Human | Esophagus | ESCC | 3.94e-25 | 7.63e-01 | 0.1371 |
51676 | ASB2 | P38T-E | Human | Esophagus | ESCC | 1.61e-10 | 6.47e-01 | 0.127 |
51676 | ASB2 | P44T-E | Human | Esophagus | ESCC | 6.87e-07 | 3.41e-01 | 0.1096 |
51676 | ASB2 | P54T-E | Human | Esophagus | ESCC | 4.62e-26 | 8.18e-01 | 0.0975 |
51676 | ASB2 | P61T-E | Human | Esophagus | ESCC | 3.49e-14 | 4.66e-01 | 0.099 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
GO:003153218 | Esophagus | ESCC | actin cytoskeleton reorganization | 72/8552 | 107/18723 | 5.03e-06 | 5.31e-05 | 72 |
GO:006056210 | Esophagus | ESCC | epithelial tube morphogenesis | 187/8552 | 325/18723 | 9.95e-06 | 9.44e-05 | 187 |
GO:00485687 | Esophagus | ESCC | embryonic organ development | 228/8552 | 427/18723 | 7.28e-04 | 3.79e-03 | 228 |
GO:00718001 | Esophagus | ESCC | podosome assembly | 15/8552 | 18/18723 | 1.20e-03 | 5.88e-03 | 15 |
GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
GO:00350512 | Esophagus | ESCC | cardiocyte differentiation | 86/8552 | 156/18723 | 1.09e-02 | 3.68e-02 | 86 |
GO:001470615 | Esophagus | ESCC | striated muscle tissue development | 197/8552 | 384/18723 | 1.46e-02 | 4.74e-02 | 197 |
GO:001049820 | Oral cavity | OSCC | proteasomal protein catabolic process | 336/7305 | 490/18723 | 5.45e-41 | 8.63e-38 | 336 |
GO:004316120 | Oral cavity | OSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 285/7305 | 412/18723 | 5.68e-36 | 5.99e-33 | 285 |
GO:003153216 | Oral cavity | OSCC | actin cytoskeleton reorganization | 65/7305 | 107/18723 | 4.25e-06 | 4.93e-05 | 65 |
GO:0071800 | Oral cavity | OSCC | podosome assembly | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
GO:00426927 | Oral cavity | OSCC | muscle cell differentiation | 175/7305 | 384/18723 | 4.79e-03 | 1.92e-02 | 175 |
GO:00147067 | Oral cavity | OSCC | striated muscle tissue development | 174/7305 | 384/18723 | 6.45e-03 | 2.40e-02 | 174 |
GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ASB2 | SNV | Missense_Mutation | c.223N>C | p.Glu75Gln | p.E75Q | Q96Q27 | protein_coding | tolerated(0.45) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ASB2 | SNV | Missense_Mutation | novel | c.922N>A | p.Leu308Ile | p.L308I | Q96Q27 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
ASB2 | insertion | Nonsense_Mutation | novel | c.870_871insAGGCTGACAGATCTGGGTGTGAATCCCTGCTGAGGCC | p.Ala291ArgfsTer11 | p.A291Rfs*11 | Q96Q27 | protein_coding | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
ASB2 | SNV | Missense_Mutation | novel | c.1736N>A | p.Ser579Asn | p.S579N | Q96Q27 | protein_coding | tolerated(0.06) | probably_damaging(0.986) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ASB2 | SNV | Missense_Mutation | c.1222N>A | p.Glu408Lys | p.E408K | Q96Q27 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ASB2 | SNV | Missense_Mutation | c.840N>C | p.Gln280His | p.Q280H | Q96Q27 | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ASB2 | SNV | Missense_Mutation | c.1273N>C | p.Tyr425His | p.Y425H | Q96Q27 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
ASB2 | SNV | Missense_Mutation | novel | c.586G>A | p.Ala196Thr | p.A196T | Q96Q27 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ASB2 | SNV | Missense_Mutation | novel | c.1505N>A | p.Gly502Asp | p.G502D | Q96Q27 | protein_coding | deleterious(0) | possibly_damaging(0.898) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ASB2 | SNV | Missense_Mutation | c.1273N>C | p.Tyr425His | p.Y425H | Q96Q27 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |